Nevertheless, the authors observed the low IDH1/2 variant allele frequency (VAF) correlated with better response to chemotherapy [77], suggesting that high mutation burden could confer resistance to induction therapy in AML cells. This evidence concerns the gene IDH1 and acute myeloid leukemia.